Compare YARW & SUNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YARW | SUNS |
|---|---|---|
| Founded | N/A | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.6M | 108.7M |
| IPO Year | 2017 | 2024 |
| Metric | YARW | SUNS |
|---|---|---|
| Price | $38.11 | $7.50 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 25.9K | ★ 78.9K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | ★ 16.17% |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | N/A | ★ $21,571,434.00 |
| Revenue This Year | N/A | $70.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.96 |
| Revenue Growth | N/A | ★ 102.96 |
| 52 Week Low | $31.55 | $7.34 |
| 52 Week High | $44.28 | $11.78 |
| Indicator | YARW | SUNS |
|---|---|---|
| Relative Strength Index (RSI) | 54.67 | 42.95 |
| Support Level | $35.50 | $7.38 |
| Resistance Level | $44.27 | $8.04 |
| Average True Range (ATR) | 2.78 | 0.20 |
| MACD | -0.46 | 0.00 |
| Stochastic Oscillator | 28.54 | 36.21 |
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.